Innocoll confirms possible takeover discussions

17 March 2017

Shares of US specialty pharma company Innocoll Holdings (Nasdaq: INNL) were up more than 37% at $1.88 by close of trading on Thursday (having exceeded the $2.00 level earlier), after the company confirmed it was in discussion which may or may not lead to an offer for the entire issued share capital of the company.

Innocoll said management has been investigating and continues to investigate strategic options for the company to maximize shareholder value. There can be no certainty that this will lead to an offer for Innocoll or any of its share capital nor as to the terms on which an offer, if any, might be made.

At the end of 2016 Innocoll took a severe battering after the US Food and Drug Administration issued a refusal to file letter for the company's product candidate for a treatment for post-surgical pain Xaracoll (bupivacaine HCl collagen-matrix implants). Xaracoll had been expected to be the first competitor to Pacira’s Exparel.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK